GlassScriptPhysician profile
Adam J Weinstein
NPI 1831216043
$7,553.67
in general payments reported to CMS, 2019-2025
45 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $81.97 · 2021: $1,056 · 2022: $1,305 · 2023: $1,638 · 2024: $1,356 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,786.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,599.98 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $604.97 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $412.88 | 2023-2025 | |
| Tg Therapeutics, INC. | $408.20 | 2023-2025 | |
| Sk Life Science, INC. | $315.32 | 2022-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $295.28 | 2019-2025 | |
| Biogen, INC. | $285.65 | 2021-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $270.76 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Argenx US, INC. | $236.65 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Merz Pharmaceuticals, LLC | $231.59 | 2021-2024 | Xeomin, Inbrija |
| Janssen Pharmaceuticals, INC | $208.95 | 2021-2023 | Ponvory |
| Amgen INC. | $196.86 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $192.63 | 2023-2025 | Ongentys, Crexont, Lyvispah |
| Alexion Pharmaceuticals, INC. | $189.12 | 2021-2025 | Ultomiris |
| Mdd US Operations, LLC | $185.11 | 2023-2025 | Gocovri, Gocovri |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $177.48 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $157.73 | 2021-2025 | Nuplazid |
| Eisai INC. | $122.00 | 2023-2025 | |
| Ucb, INC. | $113.87 | 2022-2025 | Nayzilam |
| Neurocrine Biosciences, INC. | $112.09 | 2022-2025 | Ingrezza, Ongentys |
| Ge Healthcare | $111.61 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $111.58 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $109.92 | 2022 | |
| Celgene Corporation | $101.31 | 2023-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $99.26 | 2021 | |
| Lundbeck LLC | $71.14 | 2024-2025 | Vyepti |
| Emd Serono, INC. | $64.80 | 2022-2025 | Mavenclad |
| Acorda Therapeutics, INC | $62.20 | 2021-2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $61.76 | 2020-2022 | |
| Kyowa Kirin, INC. | $60.84 | 2024 | Nourianz |
| Xeris Pharmaceuticals, INC. | $57.82 | 2022-2024 | Gvoke Hypopen, Keveyis |
| Avanir Pharmaceuticals, INC. | $52.94 | 2021-2022 | |
| Avion Pharmaceuticals | $39.36 | 2022 | |
| Impel Pharmaceuticals INC. | $34.80 | 2022-2023 | Trudhesa |
| Impel Pharmaceuticals LLC | $32.24 | 2025 | Trudhesa |
| Vertex Pharmaceuticals Incorporated | $27.35 | 2025 | |
| Banner Life Sciences, LLC | $18.69 | 2022 | |
| Medtronic, INC. | $18.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.75 | 2021 | |
| Livanova USA, INC. | $17.06 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Boston Scientific Corporation | $16.25 | 2022 | |
| Genzyme Corporation | $15.58 | 2021 | |
| Neurelis, INC. | $15.11 | 2024 | Valtoco |
| Revance Therapeutics, INC. | $13.38 | 2024 | Daxi |
| Sumitomo Pharma America, INC. | $5.25 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.